Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CIIT vs CYRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CYRX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CYRX Overall Winner 6-Pillar Tally: CIIT 1 – 5 CYRX Matrix Metrics: CIIT 1 – 9 CYRX

As of Nov 20, 2026, CryoPort, Inc. (CYRX) is the stronger overall head-to-head candidate over Tianci International, Inc. (CIIT) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CIIT carries a Unified Composite Score of 47.9/100 (HOLD) at $1.32 (N/M Forward P/E, -17.2% operating margin), whereas CYRX carries 52.0/100 (HOLD) at $19.05 (77.5x Forward P/E, -14.4% operating margin).

  • Technical & Structure Timing Caution: CIIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.1); meanwhile CYRX trades in a Markup technical trend (BREAKOUT options phase, RSI 52.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CIIT vs CYRX
CIIT NASDAQ
Tianci International, Inc. Common Stock
Computer Communications Equipment
$1.32
-8.97% 1D
Market Cap $1.7M
TTM Revenue $14M
Forward P/E N/M
Beta / 30D Vol -7.63β · 226% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.2%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $1.80 · SMA50: $2.14
CYRX NASDAQ Head-to-Head Winner
CryoPort, Inc. Common Stock
Pharmaceutical Preparations
$19.05
-2.56% 1D
Market Cap $990.2M
TTM Revenue $192M
Forward P/E 77.5x
Beta / 30D Vol 1.53β · 81% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 39.0 Fund 52.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.8% over 20 days), RSI 53
RSI-14: 52.9 · SMA20: $18.75 · SMA50: $17.85

6-Pillar Scorecard Institutional Category Breakdown (CIIT 1 – 5 CYRX)

Columns: Metric · CIIT · CYRX
1. Valuation Multiples CYRX
Forward P/E N/M 77.5x
Trailing P/E N/M 77.5x
PEG Ratio N/M N/M
EV / Revenue 0.1x 4.9x
2. Growth & Scale CYRX
Revenue Growth (YoY) -2.0% +13.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $14M $192M
Market Cap $1.7M $990.2M
3. Profitability & Quality CYRX
Gross Margin 7.4% 46.9%
Operating Margin -17.2% -14.4%
Net Profit Margin -16.7% -21.5%
Return on Equity (ROE) -57.4% -7.4%
4. Balance Sheet & Cash Flow CIIT
Cash Generation (TTM) -$3.5M -$20M
Cash Flow Margin -24.8% -10.3%
Net Cash / Leverage -$646,303 Net Debt (0.03x D/E) $48M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CYRX
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 62.6% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat CYRX
OpEx & R&D Intensity 24.6% of Rev ($3.5M) 61.3% of Rev ($118M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Integrated Freight & Logistics Operator Integrated Freight & Logistics Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CIIT (1) vs CYRX (9)
Institutional Metric CIIT CYRX Criterion Row Edge
Market Capitalization
Scale
$1.7M $990.2M Larger Scale CYRX
Trailing P/E Ratio
Valuation
N/M 77.5x Lower Multiple CYRX
Forward P/E Ratio
Valuation
N/M 77.5x Lower Multiple CYRX
Revenue Growth (YoY)
Growth
-2.0% +13.5% Higher Growth CYRX
Operating Margin (TTM)
Profitability
-17.2% -14.4% Higher Margin CYRX
Net Profit Margin
Profitability
-16.7% -21.5% Higher Margin CIIT
Return on Equity (ROE)
Capital Efficiency
-57.4% -7.4% Higher ROE CYRX
52-Week Range Position
Momentum
25% ($0–$5) 81% ($8–$22) Stronger Trend CYRX
Beta / 30D Volatility
Risk Regime
-7.63β · 226% Vol 1.53β · 81% Vol Lower Realized Risk CYRX
Unified Institutional Score
Composite Signal
47.9 / 100 (HOLD) 52.0 / 100 (HOLD) Higher Composite CYRX
Trailing 12M Revenue (USD)
Operating Scale
$14M $192M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
7.4% 46.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.5M (-$646,303 Net Debt (0.03x D/E)) -$20M ($48M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CYRX +39.49 pp
CIIT: -32.65% · CYRX: +6.84%
3M Horizon CYRX +77.42 pp
CIIT: -60.83% · CYRX: +16.59%
6M Horizon CYRX +36.82 pp
CIIT: -0.75% · CYRX: +36.07%
1Y Horizon CIIT +74.07 pp
CIIT: +199.25% · CYRX: +125.18%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CIIT Revenue CYRX Revenue CIIT Op. Margin CYRX Op. Margin Margin Leader
FY2019 N/A $30M N/A -52.1% CYRX
FY2020 N/A $80M N/A -38.1% CYRX
FY2021 N/A $220M N/A -8.0% CYRX
FY2022 $0M $240M 25.5% -13.4% CIIT
FY2023 $0M $170M -76.0% -59.6% CYRX
FY2024 $10M $160M 2.0% -77.6% CIIT
FY2025 $10M $180M -29.2% -20.9% CYRX
FY2026 $10M N/A -17.2% N/A CIIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CIIT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CIIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CYRX BREAKOUT
119d in phase · OBV DISTRIBUTION
Current IV 62.6%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CYRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CIIT Moat Profile Cyclical / Execution-Driven Positioning
Integrated Freight & Logistics Operator
Competes within the Integrated Freight & Logistics value chain with $1.7M market capitalization and -17.2% operating margin.
OpEx & R&D Reinvestment 24.6% of Rev ($3.5M)
90D Engineering Disclosures 0 Published
CYRX Moat Profile Cyclical / Execution-Driven Positioning
Integrated Freight & Logistics Operator
Competes within the Integrated Freight & Logistics value chain with $990.2M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 61.3% of Rev ($118M)
90D Engineering Disclosures 0 Published

Investor FAQ CIIT vs CYRX Key Questions & Quantitative Answers

As of Nov 20, 2026, CryoPort, Inc. (CYRX) is the stronger overall head-to-head candidate over Tianci International, Inc. (CIIT) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CIIT carries a Unified Composite Score of 47.9/100 (HOLD) at $1.32 (N/M Forward P/E, -17.2% operating margin), whereas CYRX carries 52.0/100 (HOLD) at $19.05 (77.5x Forward P/E, -14.4% operating margin). Technical & Structure Timing Caution: CIIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.1); meanwhile CYRX trades in a Markup technical trend (BREAKOUT options phase, RSI 52.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CYRX leads the Growth & Scale pillar: CIIT posts -2.0% YoY revenue growth and +0.0% YoY earnings growth on $14M TTM revenue (7.4% gross margin, -17.2% operating margin), compared with CYRX at +13.5% YoY revenue growth and +0.0% YoY earnings growth on $192M TTM revenue (46.9% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CIIT cumulative revenue shifted +0.0% while CYRX shifted +500.0%. In operating R&D and SG&A reinvestment, CIIT deploys 24.6% of Rev ($3.5M) (0 90-day corporate R&D disclosures) versus 61.3% of Rev ($118M) (0 disclosures) for CYRX.

CYRX screens cheaper on headline valuation multiples. CIIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-24.8% FCF margin), whereas CYRX trades at 77.5x Forward P/E, 77.5x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (-10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CIIT (-57.4% ROE) versus CYRX (-7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CIIT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.63β · 226% Vol realized risk). By comparison, CYRX carries 62.6% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.53β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.